Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Reichardt

Showing results (41-50 of 193) with videos related to

Pageof 20
Sort By:
Future Oncology (London, England)|May 3, 2017
Review of past and present clinical cases with a view to future treatment optionsJavier Martín-Broto, Peter Reichardt, Silvia Stacchiotti, et al.
The Oncologist|October 19, 2013
Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppressionAxel Le Cesne, Jean-Yves Blay, Peter Reichardt, et al.
Onkologie|August 8, 2012
Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcomaDaniel Pink, Janina Bertz-Lepel, Christoph Busemann, et al.
Urologia Internationalis|June 8, 2002
Pheochromocytoma and multifocal functioning paraganglioma in a 9-year-old boy with von Hippel-Lindau diseaseRalf-Bodo Tröbs, Peter Reichardt, Thomas Friedrich, et al.
Radiology|January 31, 2014
Gastrointestinal stromal tumor: a method for optimizing the timing of CT scans in the follow-up of cancer patientsHeikki Joensuu, Peter Reichardt, Mikael Eriksson, et al.
Annals of Surgical Oncology|February 11, 2016
Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01)Bernd Kasper, Viktor Gruenwald, Peter Reichardt, et al.
Future Oncology (London, England)|May 12, 2018
Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labelingPeter Reichardt, Marie-Dominique Tabone, Jaume Mora, et al.
The EMBO Journal|February 28, 2013
A role for LFA-1 in delaying T-lymphocyte egress from lymph nodesPeter Reichardt, Irene Patzak, Kristian Jones, et al.
Environmental Toxicology|January 23, 2003
Identification and quantification of in vitro adduct formation between protein reactive xenobiotics and a lysine-containing model peptidePeter Reichardt, André Schreiber, Gunnar Wichmann, et al.
Future Oncology (London, England)|May 17, 2018
Options for treating different soft tissue sarcoma subtypesIsabelle Ray-Coquard, Delphine Serre, Peter Reichardt, et al.
Pageof 20

Showing results (41-50 of 193) with videos related to

Sort By:
Pageof 20
Future Oncology (London, England)|May 3, 2017
Review of past and present clinical cases with a view to future treatment optionsJavier Martín-Broto, Peter Reichardt, Silvia Stacchiotti, et al.
The Oncologist|October 19, 2013
Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppressionAxel Le Cesne, Jean-Yves Blay, Peter Reichardt, et al.
Onkologie|August 8, 2012
Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcomaDaniel Pink, Janina Bertz-Lepel, Christoph Busemann, et al.
Urologia Internationalis|June 8, 2002
Pheochromocytoma and multifocal functioning paraganglioma in a 9-year-old boy with von Hippel-Lindau diseaseRalf-Bodo Tröbs, Peter Reichardt, Thomas Friedrich, et al.
Radiology|January 31, 2014
Gastrointestinal stromal tumor: a method for optimizing the timing of CT scans in the follow-up of cancer patientsHeikki Joensuu, Peter Reichardt, Mikael Eriksson, et al.
Annals of Surgical Oncology|February 11, 2016
Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01)Bernd Kasper, Viktor Gruenwald, Peter Reichardt, et al.
Future Oncology (London, England)|May 12, 2018
Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labelingPeter Reichardt, Marie-Dominique Tabone, Jaume Mora, et al.
The EMBO Journal|February 28, 2013
A role for LFA-1 in delaying T-lymphocyte egress from lymph nodesPeter Reichardt, Irene Patzak, Kristian Jones, et al.
Environmental Toxicology|January 23, 2003
Identification and quantification of in vitro adduct formation between protein reactive xenobiotics and a lysine-containing model peptidePeter Reichardt, André Schreiber, Gunnar Wichmann, et al.
Future Oncology (London, England)|May 17, 2018
Options for treating different soft tissue sarcoma subtypesIsabelle Ray-Coquard, Delphine Serre, Peter Reichardt, et al.
Pageof 20